Hyphens Pharma International Limited Stock Price

Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally. It operates through Specialty pharma principals; Proprietary brands; and Medical hypermart and digital segments. The Specialty Pharma Principals segment markets and sells specialty pharmaceutical products, including contrast media products, Stérimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup Lidose, and Piascledine products through distributorship or licensing, and supply agreements for the therapeutic areas, including dermatology, pediatrics and neonatology, allergy, otorhinolaryngology, orthopedics and rheumatology, radiology, cardiology and interventional cardiology, ophthalmology, gastroenterology, psychiatry, family medicine, and medical aesthetics. The Proprietary Brands segment develops, markets, and sells dermatological products, such as Cerdan, TDF, and CG 210 for the treatment of atopic dermatitis, acne, aging skin, and hyperpigmentation, as well as health supplement products under the Ocean Health brand name for heart, joint, physical, cognitive, eye, and children's health. The Medical Hypermart and Digital segment wholesales pharmaceuticals and medical supplies for healthcare professionals and institutions, and retail pharmacies through tele sales, direct sales, and online B2B platform. The company was formerly known as Hyphens Pharma International Pte Ltd and changed its name to Hyphens Pharma International Limited in May 2018. Hyphens Pharma International Limited was founded in 1998 and is headquartered in Singapore.